Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
VEGFR2/KDR/Flk-1 Antibody (2C6) - Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP281009
Description
VEGFR2/KDR/Flk-1 Monoclonal specifically detects VEGFR2/KDR/Flk-1 in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Flow (Cell Surface), Immunocytochemistry.Specifications
VEGFR2/KDR/Flk-1 | |
Monoclonal | |
1 mg/mL | |
Western Blot : 1.0 μg/mL, Immunohistochemistry, Immunocytochemistry/Immunofluorescence 1:50 - 1:100, Immunohistochemistry-Paraffin : 5 μg/mL, Flow (Cell Surface), Immunocytochemistry | |
CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, FLK1tyrosine kinase growth factor receptor, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGFR, VEGFR2, VEGFR-2 | |
Mouse | |
Protein G purified | |
RUO | |
Primary | |
Human | |
Purified |
Western Blot, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Flow Cytometry | |
2C6 | |
Unconjugated | |
PBS | |
KDR | |
Partial recombinant human VEGFR2 protein (between amino acids 300-600) [UniProt# P35968]. | |
0.1 mg | |
Angiogenesis, Apoptosis, Cancer, Cell Biology, Cellular Markers, Endothelial Cell Markers, Hematopoietic Stem Cell Markers, HIF Target Genes, Hypoxia, Phospho Specific, Signal Transduction, Stem Cell Markers, Tumor Suppressors, Tyrosine Kinases | |
3791 | |
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction